Cargando…
WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC
BACKGROUND: Aberrant expression of Wiskott–Aldrich syndrome protein interacting protein family member 1 (WIPF1) contributes to the invasion and metastasis of several malignancies. However, the role of WIPF1 in human pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. METHODS: Human pa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056910/ https://www.ncbi.nlm.nih.gov/pubmed/30041660 http://dx.doi.org/10.1186/s13046-018-0848-6 |
_version_ | 1783341414551126016 |
---|---|
author | Pan, Yu Lu, Fengchun Xiong, Ping Pan, Maoen Zhang, Zheyang Lin, Xianchao Pan, Minggui Huang, Heguang |
author_facet | Pan, Yu Lu, Fengchun Xiong, Ping Pan, Maoen Zhang, Zheyang Lin, Xianchao Pan, Minggui Huang, Heguang |
author_sort | Pan, Yu |
collection | PubMed |
description | BACKGROUND: Aberrant expression of Wiskott–Aldrich syndrome protein interacting protein family member 1 (WIPF1) contributes to the invasion and metastasis of several malignancies. However, the role of WIPF1 in human pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. METHODS: Human pancreatic cancer samples from PDAC patients were collected for methylation analysis. Bioinformatic prediction program and luciferase reporter assay were used to identify microRNAs regulating WIPF1 expression. The association between WIPF1 expression and the overall survival (OS) of patients with PDAC was evaluated by using The Cancer Genome Atlas (TCGA) database. The roles of miR-141/200c and WIPF1 on the invasion and metastasis of PDAC cells were investigated both in vitro and in vivo. RESULTS: We found that compared to the surrounding non-cancerous tissues, there was significantly increased methylation of miR-200c and miR-141 in human PDAC tissues that resulted in their silencing, whereas the members of the other cluster of miR-200 family including miR-200a, miR-200b and miR-429 were hypomethylated. Our data show that forced expression of miR-141 or miR-200c suppressed invasion and metastasis of PDAC cells both in vitro and in xenograft and identified WIPF1 as a direct target of miR-141 and miR-200c. Both miR-141 and miR-200c inhibit WIPF1 by directly interacting with its 3′-untranslated region. Remarkably, silencing of WIPF1 blocked PDAC growth and metastasis both in vitro and in vivo, whereas forced WIPF1 overexpression antagonized the tumor suppressive effect of miR-141/200c. Additionally, by using TCGA database we showed that high expression of WIPF1 correlated with poor survival in patients with PDAC. Moreover, we show that miR-141 and miR-200c blocked YAP/TAZ expression by suppressing WIPF1. CONCLUSIONS: We have identified WIPF1 as an oncoprotein in PDAC and a direct target of miR-141/miR-200c. We have also defined the miR-141/200c-WIPF1-YAP/TAZ as a novel signaling pathway that is involved in the regulation of the invasion and metastasis of human PDAC cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0848-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6056910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60569102018-07-30 WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC Pan, Yu Lu, Fengchun Xiong, Ping Pan, Maoen Zhang, Zheyang Lin, Xianchao Pan, Minggui Huang, Heguang J Exp Clin Cancer Res Research BACKGROUND: Aberrant expression of Wiskott–Aldrich syndrome protein interacting protein family member 1 (WIPF1) contributes to the invasion and metastasis of several malignancies. However, the role of WIPF1 in human pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. METHODS: Human pancreatic cancer samples from PDAC patients were collected for methylation analysis. Bioinformatic prediction program and luciferase reporter assay were used to identify microRNAs regulating WIPF1 expression. The association between WIPF1 expression and the overall survival (OS) of patients with PDAC was evaluated by using The Cancer Genome Atlas (TCGA) database. The roles of miR-141/200c and WIPF1 on the invasion and metastasis of PDAC cells were investigated both in vitro and in vivo. RESULTS: We found that compared to the surrounding non-cancerous tissues, there was significantly increased methylation of miR-200c and miR-141 in human PDAC tissues that resulted in their silencing, whereas the members of the other cluster of miR-200 family including miR-200a, miR-200b and miR-429 were hypomethylated. Our data show that forced expression of miR-141 or miR-200c suppressed invasion and metastasis of PDAC cells both in vitro and in xenograft and identified WIPF1 as a direct target of miR-141 and miR-200c. Both miR-141 and miR-200c inhibit WIPF1 by directly interacting with its 3′-untranslated region. Remarkably, silencing of WIPF1 blocked PDAC growth and metastasis both in vitro and in vivo, whereas forced WIPF1 overexpression antagonized the tumor suppressive effect of miR-141/200c. Additionally, by using TCGA database we showed that high expression of WIPF1 correlated with poor survival in patients with PDAC. Moreover, we show that miR-141 and miR-200c blocked YAP/TAZ expression by suppressing WIPF1. CONCLUSIONS: We have identified WIPF1 as an oncoprotein in PDAC and a direct target of miR-141/miR-200c. We have also defined the miR-141/200c-WIPF1-YAP/TAZ as a novel signaling pathway that is involved in the regulation of the invasion and metastasis of human PDAC cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0848-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-24 /pmc/articles/PMC6056910/ /pubmed/30041660 http://dx.doi.org/10.1186/s13046-018-0848-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Pan, Yu Lu, Fengchun Xiong, Ping Pan, Maoen Zhang, Zheyang Lin, Xianchao Pan, Minggui Huang, Heguang WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title | WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title_full | WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title_fullStr | WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title_full_unstemmed | WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title_short | WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC |
title_sort | wipf1 antagonizes the tumor suppressive effect of mir-141/200c and is associated with poor survival in patients with pdac |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056910/ https://www.ncbi.nlm.nih.gov/pubmed/30041660 http://dx.doi.org/10.1186/s13046-018-0848-6 |
work_keys_str_mv | AT panyu wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT lufengchun wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT xiongping wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT panmaoen wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT zhangzheyang wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT linxianchao wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT panminggui wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac AT huangheguang wipf1antagonizesthetumorsuppressiveeffectofmir141200candisassociatedwithpoorsurvivalinpatientswithpdac |